source
- AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidatesAstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
- Claris Biotherapeutics raises $118M Series B to advance corneal stem-cell eye dropClaris Biotherapeutics announced a $118 million Series B financing round led by Novo Holdings and supported by several venture firms. The funding will be used to move its lead candidate, CSB-001, i…